Chronos Therapeutics is a UK-based biotechnology startup pioneering in CNS (Central Nervous System) treatments for degenerative and behavioral brain diseases. Founded in 2009, the company operates a semi-virtual R&D model, collaborating with industry-leading contract research organizations to develop new chemical entities (NCEs) and repurpose existing drugs. Additionally, Chronos runs a dedicated laboratory in Oxford for drug activity screenings utilizing its proprietary platform, Chronoscreen™.
The startup focuses on fetching, discovering, and developing novel lead candidates, as well as repositioning FDA/EMA approved drugs with an emphasis on treating ALS (Lou Gehrig’s Disease), other Neurological Diseases, Fatigue, and Addictive Behavior.
In their journey, Chronos Therapeutics has successfully secured a £8.00M Venture Round investment in December 09, 2013 from Vulpes Investment Management, Odey Asset Management, and the University of Oxford, reflecting a strong backing from notable investors and academic institutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £8.00M | 3 |
|
09 Dec 2013 |
No recent news or press coverage available for Chronos Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
